Dextrose and Sodium Chloride
RxNorm 1794902· DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE· INTRAVENOUS
ICU Medical Inc.
Indications and usage
INDICATIONS AND USAGE Intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.
Dosage and administration
DOSAGE AND ADMINISTRATION The dose is dependent upon the age, weight and clinical condition of the patient. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS . Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Warnings
WARNINGS Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Excessive administration of potassium-free solutions may result in significant hypokalemia. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
Contraindications
CONTRAINDICATIONS None known.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- vomiting39
- nausea34
- hyponatraemia28
- ascites27
- constipation27
- sepsis27
- abdominal distension26
- abdominal pain26
- general physical health deterioration25
- off label use25
- appendicitis24
- appendicolith24
- ventricular fibrillation24
- anaemia23
- cardiogenic shock23
- multiple organ dysfunction syndrome22
Adverse reactions (label)
ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
KR · 한국Products in Korea (55)
- 뮤로128점안액2%(염화나트륨)(주)바슈헬스코리아
- 뮤로128점안액5%(염화나트륨)(주)바슈헬스코리아
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 대한관류용멸균생리식염수대한약품공업(주)
- 대한3%염화나트륨액대한약품공업(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
View more: Full FDA label on DailyMed →Label effective 20251102